GSK plc (GSK)
| Market Cap | 102.74B +36.3% |
| Revenue (ttm) | 43.29B +4.0% |
| Net Income | 7.70B +84.9% |
| EPS | 1.88 +86.6% |
| Shares Out | 4.02B |
| PE Ratio | 13.35 |
| Forward PE | 10.22 |
| Dividend | $1.77 (3.45%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 3,154,093 |
| Open | 51.56 |
| Previous Close | 51.53 |
| Day's Range | 51.14 - 51.80 |
| 52-Week Range | 35.45 - 61.70 |
| Beta | 0.30 |
| Analysts | Hold |
| Price Target | 76.86 (+49.59%) |
| Earnings Date | Apr 29, 2026 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for GSK stock is "Hold." The 12-month stock price target is $76.86, which is an increase of 49.59% from the latest price.
News
Notable ETF Inflow Detected - FENI, BTI, AER, GSK
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Fidelity Enhanced International ETF (Symbol: FENI) where we have detec...
GSK Expands Arexvy Vaccine Eligibility for RSV Protection
GSK Expands Arexvy Vaccine Eligibility for RSV Protection
GSK announces Japan’s MHLW expanded eligible population for Arexvy
GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has expanded the eligible population for Arexvy, to include adults aged 18 to 49 years at increased risk…
GSK: Japan's MHLW Expands Eligible Population For Arexvy
(RTTNews) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for RSV vaccine, Arexvy, to include adults aged 18 to 49 years at in...
GSK enters into exclusive strategic collaboration with Sino Biopharm
GSK (GSK) announced that it has entered into an exclusive strategic collaboration with Sino Biopharmaceutical (SBMFF), through its subsidiary Chia Tai Tianqing Pharmaceutical Group, or CTTQ, to accele...
GSK Partners with China National Pharmaceutical for Bepirovirsen Development
GSK Partners with China National Pharmaceutical for Bepirovirsen Development
GSK Launches Final GBP 0.18 Bln Tranche Of GBP 2 Bln Share Buyback
(RTTNews) - GSK plc (GSK, GSK.L, GS71.DE), on Monday announced the commencement of the fifth and final tranche of its 2 billion pounds share buyback program, covering up to about 0.18 billion pounds, ...
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment
GSK on Monday said it had entered into a strategic collaboration with Hong Kong-listed Sino Biopharmaceutical to accelerate the launch of its hepatitis B treatment bepirovirsen in mai...
Halozyme announces global collaboration and license agreement with GSK
Halozyme Therapeutics (HALO) announced the company entered into a global collaboration and license agreement with GSK (GSK). Under the collaboration, GSK has licensed Halozyme’s ENHANZE drug delivery ...
GSK partners with Julie Bowen, Ty Burrell to raise meningitis awareness
GSK (GSK) announced new campaign spokespeople, Julie Bowen and Ty Burrell, as part of its Ask2BSure public health campaign to raise awareness and encourage parents to “ask to be sure”…
Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults.
GSK price target lowered to 2,100 GBp from 2,250 GBp at Citi
Citi lowered the firm’s price target on GSK (GSK) to 2,100 GBp from 2,250 GBp and keeps a Neutral rating on the shares.
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat
Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely need...
GSK PLC (GSK) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Pipeline Expansion
GSK PLC (GSK) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Pipeline Expansion
GSK Faces Setback as Nivisnebart Trial for Alzheimer's Discontinued
GSK Faces Setback as Nivisnebart Trial for Alzheimer's Discontinued
A Look at GSK PLC (GSK) After 5.6% Decline -- GF Value $43.80 vs Price $51.40
A Look at GSK PLC (GSK) After 5.6% Decline -- GF Value $43.80 vs Price $51.40
Big pharma can boost Britain: Labour must not let our flagship firms drift away, says RUTH SUNDERLAND
One area where the UK still performs well on an international stage is pharmaceuticals, led by AstraZeneca and GSK.
AstraZeneca (AZN) and GSK Report Strong Q1 Earnings Amid Pricing Policy Concerns
AstraZeneca (AZN) and GSK Report Strong Q1 Earnings Amid Pricing Policy Concerns
GSK Reports Strong Q1 2026 Results with Revenue Growth
GSK Reports Strong Q1 2026 Results with Revenue Growth
GSK Declares Quarterly Dividend of $0.44, Initiates £2 Billion Buyback
GSK Declares Quarterly Dividend of $0.44, Initiates £2 Billion Buyback
GSK Raises 2031 Sales Forecast to Over GBP 40 Billion
GSK Raises 2031 Sales Forecast to Over GBP 40 Billion
GSK Expects Steady Growth Through 2026
GSK Expects Steady Growth Through 2026
GSK Reports Strong Q1 Sales Growth and Advancements in R&D
GSK Reports Strong Q1 Sales Growth and Advancements in R&D